Business Wire

TECKRO

20.5.2021 15:06:47 CEST | Business Wire | Press release

Share
Teckro Expands Its Leadership Position in Clinical Trials With New Hires Malia Lewin and Silvina Baudino to Scale Its Global Market Strategy

Teckro , creator of the only clinical trials platform that facilitates collaboration and real-time decision-making between and among study stakeholders, today announces two key hires: Malia Lewin as global head of strategy and Silvina Baudino to lead the Teckro site strategy. They are the latest experienced veterans to join Teckro’s leadership team.

Other notable hires since the start of the year, include:

  • Former Veeva Systems sales leaders Ciaran Avitabile and Jeremy Schwarz join as Teckro global head and US head of sales, respectively;
  • Previous Salesforce solution engineering leader Brian Sharkey joins to build Teckro’s global solution consulting function;
  • Cheryl Murphy, with 20+ years of experience in the pharmaceutical industry, joins as Teckro VP of customer engagement and delivery where she will lead operational excellence for a world-class customer experience.

Malia Lewin to Lead Teckro’s Strategy for Optimal Market and Product Fit

Malia Lewin has nearly 20 years of experience in the biopharma industry, serving in a variety of roles to champion new ideas, innovation and technological advancements in life sciences. Most recently, Malia was chief business officer at CherryCircle Software, a maker of cloud-based software for pharmaceutical manufacturing. Among her other roles, she served as global director of oncology strategy at Veeva Systems.

Malia says, “While clinical research pushes forward incredible scientific advancements, the management of clinical trial operations is woefully behind. This creates friction that needlessly impacts the time and cost of delivering new treatments. Teckro’s platform changes the game by allowing a seamless flow of vital information between sites and sponsors. This enables faster, safer, more efficient trials and an improved path for life-saving treatments to people around the world. ”

Silvina Baudino to Champion Teckro Requirements for Sites’ Needs

Also joining Teckro’s strategy team, Silvina Baudino brings more than 20 years of clinical trial industry experience, most recently as director of strategic site networks for IQVIA. Her career has encompassed a diverse range of responsibilities, including building and implementing innovative site-centric delivery models as well as creating strategies to improve quality and accessibility to clinical trials for patients globally.

“While public awareness and appreciation for clinical research improved with the pandemic, research site staff are struggling to work through backlogs of trials that were put on hold or delayed due to COVID-19,” Silvina explains. “Teckro is uniquely positioned to help site staff manage their demanding workloads to deliver the best outcomes for patients and preserve the quality of the research data.”

CEO Gary Hughes reflects on the current strength of Teckro, saying: “The depth of the expertise of our leadership team is testament to the belief in Teckro’s mission and our positive impact on clinical trials operations. This all-star team of leaders gives confidence to the rest of our staff, prospective employees, and our customers that we can continue to modernize and simplify clinical operations and accelerate the pace of clinical research.

Watch this short Q&A with Malia and Silvina to hear their thoughts on joining Teckro on International Clinical Trials Day and how they believe the future of clinical trials will evolve.

About Teckro

Teckro’s cloud-based clinical trial platform connects research sites, monitors and study teams with access to critical information, real-time decision support, and vital insights into clinical operations and trial performance. Teckro is used at more than 20,000 research sites and by thousands of investigators around the world. The company works with six out of the top 10 pharmaceutical companies as well as emerging biotechs. A number of trials run on Teckro are now starting to report success metrics in meeting endpoints, and others have been granted priority review by regulators in the US and Europe.

More Information:

Link:

ClickThru

Social Media:

https://www.facebook.com/teckroofficial/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye